Alexis Borisy has $200M to back a market-based plan aimed at curing America’s drug pricing ‘sickness’
SAN FRANCISCO — As a high-profile figure in the biotech boom that has transformed the industry over the last decade, Alexis Borisy co-founded a slew of startups. One of those companies is Blueprint Medicines, where he has been on the board since 2011.
A few days ago, Borisy’s biotech reached a milestone every upstart yearns for. The FDA approved their first precision cancer medicine — and the executive team immediately priced it in the US at a staggering $32,000 a month, almost twice what some analysts had expected. If it performs according to the US model, that’s far more than any other payer will cover in the rest of the world — even after any negotiated discount. And that’s just the latest in a long lineup of new drugs from companies big and small bidding up ever-higher price tags.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 70,500+ biopharma pros reading Endpoints daily — and it's free.